Genentech reports fenebrutinib Phase III results for PPMS

​Genentech has reported new data from the Phase III FENtrepid trial of fenebrutinib, an investigational Bruton’s tyrosine kinase inhibitor, for treating PPMS.

The post Genentech reports fenebrutinib Phase III results for PPMS appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Philips unveils new InkSpace Snuggle coil for paediatric imaging
Lyell doses first patient in Phase III trial for LBCL
Natus Sensory acquires medical technology company TheraB Medical
MSD receives FDA approval for Keytruda combo to treat ovarian cancer
Patient enrolment concludes in Senti Biosciences’ SENTI-202 Phase I trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us